Literature DB >> 24115812

HER2 therapies and gastric cancer: a step forward.

Ramon Andrade de Mello1, Andrea Marin Marques, António Araújo.   

Abstract

Gastric cancer usually is diagnosed in advanced stages and thus current medical practice affords limited therapeutic options. However, recent studies established the role of human epidermal growth factor receptor 2 (HER2) in clinical management. Trastuzumab, an anti-HER2 monoclonal antibody, acquired a main role in advanced gastric cancer harboring HER2 overexpression and/or amplification improving survival to 17.1 mo according to trastuzumab for gastric cancer phase III trial results. Also, new promising drugs, such as c-Met inhibitors, are in development and assessment for this setting. Certainly, novel drugs will emerge in the next feel years for help oncologists improve clinical management of advanced gastric cancer providing higher survival and quality of life. In this mini-review we will discuss some issues in this regard and provide an actual overview of this setting.

Entities:  

Keywords:  Gastric cancer; Human epidermal growth factor receptor 2; Lapatinib; Pertuzumab; Trastuzumab; c-Met

Mesh：

Substances：

Year:  2013        PMID： 24115812      PMCID： PMC3787345          DOI： 10.3748/wjg.v19.i37.6165

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  43 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

2.  Prognostic significance of HER2/neu expression in gastric cancer.

Authors:  Julian Ananiev; Maya Gulubova; Irena Manolova; Georgi Tchernev
Journal:  Wien Klin Wochenschr       Date:  2011-07-11       Impact factor: 1.704

Review 3.  Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

Authors:  F De Vita; F Giuliani; N Silvestris; G Catalano; F Ciardiello; M Orditura
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

Review 4.  Anti-HER agents in gastric cancer: from bench to bedside.

Authors:  Lorenzo Fornaro; Maurizio Lucchesi; Chiara Caparello; Enrico Vasile; Sara Caponi; Laura Ginocchi; Gianluca Masi; Alfredo Falcone
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

5.  Chylous ascites due to signet ring cell gastric adenocarcinoma.

Authors:  R A de Mello; T Gregório; T Cardoso
Journal:  Niger J Clin Pract       Date:  2012 Oct-Dec       Impact factor: 0.968

6.  Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Authors:  Mark Barok; Minna Tanner; Katri Köninki; Jorma Isola
Journal:  Cancer Lett       Date:  2011-04-01       Impact factor: 8.679

7.  Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  Luca Gianni; Anna Lladó; Giulia Bianchi; Javier Cortes; Pirkko-Liisa Kellokumpu-Lehtinen; David A Cameron; David Miles; Stefania Salvagni; Andrew Wardley; Jean-Charles Goeminne; Veronica Hersberger; José Baselga
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 8.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

9.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.

Authors:  S Uchino; H Tsuda; K Maruyama; T Kinoshita; M Sasako; T Saito; M Kobayashi; S Hirohashi
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

10.  HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

Authors:  Heike Grabsch; Shivan Sivakumar; Sally Gray; Helmut E Gabbert; Wolfram Müller
Journal:  Cell Oncol       Date:  2010       Impact factor: 6.730
View more
  20 in total

1.  New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.

Authors:  Juliane M Jürgensmeier; Joseph P Eder; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-09-01       Impact factor: 12.531

Review 2.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 3.  Pathogenetic mechanisms in gastric cancer.

Authors:  Jing Shi; Yi-Ping Qu; Peng Hou
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 4.  Proteomic and metabolic prediction of response to therapy in gastric cancer.

Authors:  Michaela Aichler; Birgit Luber; Florian Lordick; Axel Walch
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 5.  Molecular pathways: HER3 targeted therapy.

Authors:  Kinisha Gala; Sarat Chandarlapaty
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

Review 6.  Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

Authors:  Giandomenico Roviello; Roberto Petrioli; Luigi Marano; Karol Polom; Daniele Marrelli; Armando Perrella; Franco Roviello
Journal:  Gastric Cancer       Date:  2015-09-02       Impact factor: 7.370

Review 7.  An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa.

Authors:  Hiroyuki Yamamoto; Yoshiyuki Watanabe; Tadateru Maehata; Ryo Morita; Yoshihito Yoshida; Ritsuko Oikawa; Shinya Ishigooka; Shun-Ichiro Ozawa; Yasumasa Matsuo; Kosuke Hosoya; Masaki Yamashita; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Hiroshi Yasuda; Yasuhisa Shinomura; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

8.  Assessment of Systemic Inflammatory Response and Nutritional Markers in Patients With Trastuzumab-treated Unresectable Advanced Gastric Cancer.

Authors:  Tsutomu Namikawa; Masahiro Maeda; Keiichiro Yokota; Nobuhisa Tanioka; Ian Fukudome; Jun Iwabu; Masaya Munekage; Sunao Uemura; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 9.  Theranostic applications of antibodies in oncology.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Sandra Heskamp; Carla M L van Herpen; Wim J G Oyen; Winette T A van der Graaf; Otto C Boerman
Journal:  Mol Oncol       Date:  2014-03-21       Impact factor: 6.603

Review 10.  Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer.

Authors:  Byungho Lim; Jong-Hwan Kim; Mirang Kim; Seon-Young Kim
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.